Chugai Pharmaceutical revenue and financials
¥6,120.00Change from previous close: +0.51%Absolute change: +¥31.00
In the fiscal year ended December 2025, Chugai Pharmaceutical reported revenue of ¥1.26T (+7.46% year over year). Net income was ¥434.01B, a net margin of 34.5%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +7.46%
- 2025 vs 2024
- Net income growth
- +12.06%
- 2025 vs 2024
- Net margin
- 34.5%
- 2024: 33.1%
Financial data
Amounts in millions of JPY; per-share values in JPY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 1,257,941 | 1,170,611 | 1,111,367 | 1,259,726 | — |
| Cost of revenue | 363,690 | 339,409 | 413,306 | 476,251 | — |
| Gross profit | 894,251 | 831,201 | 698,061 | 783,475 | — |
| Selling, general and administrative | 116,461 | 110,098 | 112,580 | 100,477 | — |
| Research and development | 187,598 | 181,440 | 174,868 | 149,626 | — |
| Operating income | 598,833 | 542,002 | 439,174 | 533,308 | — |
| EBIT | 598,014 | 542,002 | 443,848 | 531,227 | — |
| EBITDA | 598,014 | 542,002 | 443,848 | 531,227 | — |
| Interest expense | 207 | — | 27.0 | 61.0 | 48.0 |
| Pre-tax income | 597,807 | 543,034 | 443,821 | 531,166 | — |
| Income tax | 163,794 | 155,717 | 118,349 | 156,737 | — |
| Net income | 434,012 | 387,317 | 325,472 | 374,429 | — |
| Net income to common shareholders | 434,012 | 387,317 | 325,472 | 374,429 | — |
| Basic EPS | 263.73 | 235.39 | 197.83 | 227.64 | — |
| Diluted EPS | 263.72 | 235.36 | 197.80 | 227.57 | — |
| Average shares (basic) | 1,646 | 1,645 | 1,645 | 1,645 | — |
| Average shares (diluted) | 1,646 | 1,646 | 1,645 | 1,645 | — |